drugset / Trial / NCT00762957

Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

NCT00762957

Phase 3 Terminated 15 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus

Timeline

Start
2004-11
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IMIGLITAZAR Small molecule 16 mg Oral
Subject IMIGLITAZAR Small molecule 32 mg Oral
Comparator Metformin Small molecule Oral

Indications